Previous 10 | Next 10 |
Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover ...
Commercial-stage biotech BioCryst Pharmaceuticals ( NASDAQ: BCRX ) gained ~16% in the pre-market Thursday after the company announced that the FDA lifted its partial clinical hold on the development program of kidney disease drug BCX9930. The program includes two pivot...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: BioCryst Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q2 GAAP EPS of -$0.32 beats by $0.03 . Revenue of $65.53M (+31.1% Y/Y) beats by $1.7M . FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million Based on the reduced spending ...
—Q2 2022 ORLADEYO net revenue of $65.2 million— —FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million— RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:...
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinica...
BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.35 (-45.8% Y/Y) and the consensus Revenue Estimate is $63.83M (+27.7% Y/Y). Over the last 1 year, BCRX ...
It's really exciting to see triple-digit revenue growth. ShockWave Medical (NASDAQ: SWAV) and BioCryst Pharmaceuticals (NASDAQ: BCRX) are blowing the roof off right now, with 194% and 162% sales increases, respectively. Sometimes you see astronomical growth in a hea...
Shares of rare disease biopharma BioCryst Pharmaceuticals are down some 40% since announcing a voluntary halt to three trials involving its BCX9930 program on April 8, 2022. The FDA has subsequently stepped in with a partial hold on the studies with no news expected on next steps unti...
RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022. BioCryst management will host a conference call and webcas...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...